Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

July 12, 2005 09:00 ET

Novadaq Receives U.S. Patent for Intra-Operative Imaging Procedure Using the SPY System

TORONTO, ONTARIO--(Marketwire - July 12, 2005) - Novadaq Technologies Inc. (TSX:NDQ) today announced that it has been granted a patent by the United States Patent and Trademark Office for the SPY™ Intra-operative Imaging System (SPY System). The SPY System enables real-time visual confirmation of revascularization during heart bypass surgery thereby allowing bypass graft technical errors to be detected and corrected while the patient is still in the operating room.

"The claims of this patent provide protection for our proprietary SPY System technology and our intra-operative imaging procedure," said Arun Menawat, President and CEO of Novadaq Technologies. “This U.S. patent supports our global strategy to build a strong IP portfolio to protect our innovative vascular imaging technology products and emerging pipeline.”

The patent, U.S. 6,915,154 B1, is titled "Method and Apparatus For Performing Intra-Operative Angiography" and describes the SPY intra-operative fluorescent imaging system that enables cardiac surgeons to confirm the location of coronary arteries during coronary artery bypass graft (CABG) procedures and visually assess and validate the functionality of bypass grafts.

About the SPY Intra-operative Imaging System

Novadaq’s SPY Intra-operative Imaging System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for use during CABG surgery. The SPY System is the first intra-operative fluorescent imaging system that enables cardiac surgeons to confirm the location of the coronary arteries and assess bypass graft functionality during coronary artery bypass procedures. The SPY System enables the surgeon to view, record, replay, print and archive high quality real-time images of the coronary arteries and bypass grafts.

About Novadaq Technologies

Novadaq™ Technologies (TSX:NDQ) develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseases and conditions. Novadaq's SPY System enables surgeons to visually assess coronary vasculature and bypass graft functionality during the course of CABG surgery. Novadaq's ophthalmic product, OPTTX™ System, is aimed at the diagnosis, evaluation and treatment of Wet Age Related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY. The OPTTX System is currently being evaluated in clinical trials.

For more information, please visit the company's website at www.novadaq.com.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information